The Developmental Research Program of the University of Pittsburgh Head and Neck Cancer SPORE will continue to be carried out for the purpose of identifying and facilitating innovative new pilot projects in head and neck cancer research. The specific goals of this Program are: 1) to provide seed funding opportunities for initial investigation of promising novel research in head and neck cancer;2) to stimulate basic, clinical, and translational head and neck cancer research in areas of high priority to the Head and Neck Cancer SPORE;3) to facilitate development of pilot projects into full project status in the Head and Neck Cancer SPORE or to be competitive for independent Investigator-initiated proposals to other funding agencies;and 4) to increase the visibility of Head and Neck Cancer SPORE activities and increase participation among the institution's clinicians and researchers. Our design for the Developmental Research Program in this renewal application is similar to the process used during the first grant period, which proved successful. Drs. William L. Bigbee, Susanne M. Gollin and Jonas T. Johnson, with ongoing experience in administering this Developmental Program, will continue to provide leadership for translational research. The Developmental Research Program will utilize institutional web-based resources and printed announcements to notify the research community at the University of Pittsburgh and Carnegie Mellon University of the availability of research funds to support pilot projects in head and neck cancer. In response to the new SPORE guidelines encouraging inter-institutional collaboration, we will also make the program available to our sister Cancer Centers in Philadelphia, who are part of the stateside Pennsylvania Cancer Control Consortium (PAC-3) initiative. A standing Developmental Research Program Committee, together with ad hoc reviewers with specific expertise as needed drawn from the UPCI, UPMC, the Head and Neck Cancer SPORE External Advisory Board, or other Head and Neck SPOREs will provide rigorous and consistent peer review of the solicited project proposals. The proposed Developmental Research Program budget will include $100,000 per year in funds form the NCI through this proposal, together with an additional $100,000 per year in matching funds from the Department of Otolaryngology (through the Eye and Ear Foundation of Pittsburgh) and the UPCI. Proposals will be solicited and reviewed on an annual basis and grants of $30,000-$50,000 per year for 1-2 years will be awarded to the most meritorious proposals. These activities of the Developmental Research Program will continue to stimulate innovative research toward meeting the translational goals of the Head and Neck Cancer SPORE: reduction in the incidence, morbidity, and mortality from head and neck cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097190-09
Application #
8541593
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
9
Fiscal Year
2013
Total Cost
$166,476
Indirect Cost
$86,635
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Pai, Sara I; Jack Lee, J; Carey, Thomas E et al. (2018) HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncol 77:92-97
Shayan, Gulidanna; Kansy, Benjamin A; Gibson, Sandra P et al. (2018) Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res 24:62-72
Lee, Yoon Se; Johnson, Daniel E; Grandis, Jennifer R (2018) An update: emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs :1-17
Johnson, Daniel E; O'Keefe, Rachel A; Grandis, Jennifer R (2018) Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15:234-248
Close, David A; Camarco, Daniel P; Shan, Feng et al. (2018) The Generation of Three-Dimensional Head and Neck Cancer Models for Drug Discovery in 384-Well Ultra-Low Attachment Microplates. Methods Mol Biol 1683:355-369
Yang, Xi; Xia, Rui; Yue, Cuihua et al. (2018) ATF4 Regulates CD4+ T Cell Immune Responses through Metabolic Reprogramming. Cell Rep 23:1754-1766
Njatcha, Christian; Farooqui, Mariya; Kornberg, Adam et al. (2018) STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer. Mol Cancer Ther 17:1917-1926
Johnston, Paul A; Sen, Malabika; Hua, Yun et al. (2018) High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. Methods Mol Biol 1683:229-244

Showing the most recent 10 out of 310 publications